摘要
Hepatocellular carcinoma(HCC)is the most common type of liver cancer with a high mortality rate worldwide.The percentage of HCC patients with vascular invasion is high.However,tumor thrombus in the hepatic vein(HVTT)has a lower incidence than tumor thrombus in the portal vein(PVTT).Conventionally,HCC patients with HVTT are treated the same as HCC patients with PVTT and offered sorafenib or other systemic agents.However,according to recent studies,it is evident that HCC with HVTT shows different outcomes when classified into different subgroups.In this review,we discuss the recent progress and changes in treatment of HCC with HVTT.
基金
Supported by the National Natural Science Foundation of China,No.81802767 and No.81860117.
